RPRX earnings analysis
What we found in RPRX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Royalty Pharma plc reported a first-quarter 2026 net income of $294.7 million, up 23.1% year-over-year, and total operating revenue of $630.6 million, reflecting an 11% increase compared to the previous year. EBITDA jumped to 722.1 million, driven primarily by portfolio receipts boosted by strong performance in key products, despite a significant financial royalty asset impairment of $69.4 million reported during the period. The company raised its full-year guidance for portfolio receipts due to solid performance across multiple segments.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Growth
- Total revenue increased to $630.6 million, a rise of 11% from $568.2 million in Q1 2025.
- Strong EPS Performance
- The diluted EPS rose to $0.53, compared to $0.43 in Q1 2025, exceeding expectations.
- Portfolio Receipts Surge
- Total portfolio receipts reached $925.4 million, a 10% year-over-year increase.
- Segment Performance Highlights
- Royalty receipts from the cystic fibrosis franchise grew by 1.4% to $253.2 million.
- Strategic Adjustments
- Management retained robust cash liquidity, with cash provided by operating activities rising to $718.2 million, up from $596.1 million.
- Successful Debt Management
- Interest expense climbed to $93.7 million, primarily due to higher debt levels resulting from recent financing.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Financial Royalty Asset Impairment
- Significant impairment charge of $69.4 million related to Tazverik due to market withdrawal.
- Interest Rate Risks
- Interest expense increased by 43.6% to $93.7 million, raising concerns over rising costs associated with debt financing.
- Dependence on Key Products
- 62% of royalty receipts were derived from the top five products, exposing significant revenue risks.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.53
- Segment
- Cystic fibrosis
- Segment
- Evrysdi
- Segment
- Tremfya
- Segment
- Voranigo
- Segment
- Trelegy
What they said about what is next.
Raised full-year 2026 guidance for portfolio receipts from previous $3,275 million to $3,450 million.
The filing reads better than the one before it.
What came before.
- 10-K · February 11, 2026
- Royalty Pharma (RPRX) positions itself as the largest buyer of biopharmaceutical royalties with scale, high cash conversion and a disciplined capital-allocation framework. In 2025 the company generated $3.3 billion of…
- 10-Q · May 8, 2025
- Royalty Pharma reported Q1 2025 income and other revenues of $568,247,000 (vs $567,978,000 in Q1 2024) and generated operating income of $534,182,000 (versus an operating loss of $73,774,000 in Q1 2024). Diluted Class A…
- 10-K · February 12, 2025
- Royalty Pharma (RPRX) positions itself as the largest buyer of biopharmaceutical royalties with a capital-efficient, high-cash-conversion model focused on long-duration royalty assets. In 2024 the company generated $2.8…
- 10-Q · August 8, 2024
- Royalty Pharma reported quarter revenues of $537,267,000 (three months ended June 30, 2024), essentially flat versus $538,202,000 in Q2 2023, while diluted earnings per Class A share fell to $0.23 from $0.50 a year…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing RPRX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever